Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

iPSC Neurodegenerative Disease Initiative isogenic CAG repeat iPSC line for Huntington's disease.

bioRxiv : the preprint server for biology·2026
Same author

R1398 is the GTP-𝛾-phosphate sensor that drives the ROC G-domain switching mechanism unique to Parkinson's disease-associated LRRK2.

Research square·2026
Same author

Recruitment strategies in a diverse Parkinson's disease cohort: lessons from the East London Parkinson's Disease Project.

BMJ neurology open·2026
Same author

Repeat expansions in Parkinson's disease and parkinsonism across ancestries: insights from a global genetic cohort.

medRxiv : the preprint server for health sciences·2026
Same author

Sternum-worn vibrotactile device in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot trial.

NPJ Parkinson's disease·2026
Same author

Depressing temporal experiences: the COVID-19 Pandemic lockdown in Victoria, Australia.

Psychopathology·2026

Related Experiment Video

Updated: Sep 15, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.5K

MEDICATION EXPOSURE AND NEURODEGENERATIVE DISEASE RISK ACROSS NATIONAL BIOBANKS.

Kristin S Levine1,2, Lana Sargent1,3, Emma N Somerville4

  • 1Center for Alzheimer's and Related Dementias, National Institute on Aging, Bethesda, MD, USA.

Medrxiv : the Preprint Server for Health Sciences
|July 17, 2025
PubMed
Summary
This summary is machine-generated.

This study analyzed medication use and neurodegenerative disorder (NDD) risk in large biobanks. Some common medications were linked to increased NDD risk, while others, including antibiotics and statins, showed a protective association.

Keywords:
Epidemiology: Environmental risk factors Abstract SubmissionTheme A: β-Amyloid Diseases » A05.e. Genetics

More Related Videos

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.1K
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.9K

Related Experiment Videos

Last Updated: Sep 15, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.5K
Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.1K
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.9K

Area of Science:

  • Pharmacovigilance
  • Neuroepidemiology
  • Computational Biology

Background:

  • Neurodegenerative disorders (NDDs) like Alzheimer's and Parkinson's disease are complex, influenced by age, genetics, and environment.
  • Understanding medication's role in NDD risk is crucial for patient care and drug development.

Purpose of the Study:

  • To investigate associations between prescription medication exposure and the risk of developing NDDs.
  • To assess both lifetime and delayed (≥10 years) medication exposure risks for NDDs.
  • To identify specific medications that may increase or decrease NDD risk.

Main Methods:

  • Utilized large-scale UK Biobank (UKB) and All of Us (AoU) datasets comprising over 700,000 individuals.
  • Employed Cox proportional hazard models in a two-stage discovery and replication cohort design.
  • Analyzed 480 prescription medication exposures, adjusting for comorbidities and APOE-ε4 status.

Main Results:

  • Identified 241 significant medication-NDD associations in the discovery cohort, with 157 replicated.
  • Fifteen associations remained significant after adjustments, with most indicating increased NDD risk.
  • Found inverse associations for two antibiotics, one proton pump inhibitor, and one statin with NDD risk.

Conclusions:

  • Large-scale analysis identified and replicated medication-NDD associations, highlighting potential risks and protective effects.
  • Findings suggest certain common medications may influence NDD development.
  • Further longitudinal and mechanistic studies are necessary to confirm causality.